KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Goodwill: 2009-2025

Historic Goodwill for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $1.8 billion.

  • Jazz Pharmaceuticals' Goodwill rose 1.27% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 1.27%. This contributed to the annual value of $1.7 billion for FY2024, which is 2.10% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Goodwill stood at $1.8 billion for Q3 2025, which was down 0.89% from $1.8 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Goodwill's 5-year high stood at $1.9 billion during Q2 2021, with a 5-year trough of $938.4 million in Q1 2021.
  • Its 3-year average for Goodwill is $1.8 billion, with a median of $1.7 billion in 2023.
  • Its Goodwill has fluctuated over the past 5 years, first soared by 105.63% in 2021, then fell by 13.89% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Goodwill (Quarterly) stood at $1.8 billion in 2021, then declined by 7.38% to $1.7 billion in 2022, then grew by 3.57% to $1.8 billion in 2023, then fell by 2.10% to $1.7 billion in 2024, then rose by 1.27% to $1.8 billion in 2025.
  • Its Goodwill was $1.8 billion in Q3 2025, compared to $1.8 billion in Q2 2025 and $1.8 billion in Q1 2025.